{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:33:26Z","timestamp":1775136806227,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ghir.2025.101669","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:22:05Z","timestamp":1760538125000},"page":"101669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dynamic changes in IGF-1 levels during cabergoline therapy in prolactinoma"],"prefix":"10.1016","volume":"82","author":[{"given":"Ahmet Numan","family":"Demir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alara","family":"Birol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilan","family":"Ozaydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehra","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinar","family":"Kadioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ghir.2025.101669_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","article-title":"The epidemiology of prolactinomas","volume":"8","author":"Ciccarelli","year":"2005","journal-title":"Pituitary"},{"issue":"12","key":"10.1016\/j.ghir.2025.101669_bb0010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement [published correction appears in Nat Rev Endocrinol. 2024 Jan;20(1):62. doi: 10.1038\/s41574-023-00916-2]","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.ghir.2025.101669_bb0015","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.ghir.2025.101669_bb0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1055\/a-2364-6027","article-title":"Role of medical and surgical treatment in management of the patients with prolactinoma: a single-center experience","volume":"132","author":"Zulfaliyeva","year":"2024","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"1","key":"10.1016\/j.ghir.2025.101669_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly [published correction appears in Nat Rev Dis Primers. 2019 Oct 21;5(1):72. doi: 10.1038\/s41572-019-0129-5]","volume":"5","author":"Colao","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.ghir.2025.101669_bb0030","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.ghir.2025.101669_bb0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s11102-018-0891-5","article-title":"IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas","volume":"21","author":"Akirov","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ghir.2025.101669_bb0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11102-019-01011-4","article-title":"Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients","volume":"23","author":"Iglesias","year":"2020","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.ghir.2025.101669_bb0045","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ghir.2025.101669_bb0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12902-024-01622-4","article-title":"Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight","volume":"24","author":"Caprio","year":"2024","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"10.1016\/j.ghir.2025.101669_bb0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12020-020-02557-1","article-title":"Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated","volume":"72","author":"Andereggen","year":"2021","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.ghir.2025.101669_bb0060","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ncpendmet0427","article-title":"Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1","volume":"3","author":"LeRoith","year":"2007","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2025.101669_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1142644","article-title":"New insights on the cardiovascular effects of IGF-1","volume":"14","author":"Macvanin","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"9","key":"10.1016\/j.ghir.2025.101669_bb0070","doi-asserted-by":"crossref","first-page":"e850","DOI":"10.1210\/clinem\/dgad105","article-title":"Insulin-like growth factor 1 and risk of cardiovascular disease: results from the UK biobank cohort study","volume":"108","author":"Lin","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5 Pt B","key":"10.1016\/j.ghir.2025.101669_bb0075","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.bbadis.2017.08.029","article-title":"Insulin-like growth factor-1 signaling in cardiac aging","volume":"1864","author":"Lee","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"7","key":"10.1016\/j.ghir.2025.101669_bb0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.tem.2009.04.002","article-title":"Role of IGF-I in skeletal muscle mass maintenance","volume":"20","author":"Clemmons","year":"2009","journal-title":"Trends Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.ghir.2025.101669_bb0085","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.2337\/db11-1488","article-title":"Insulin-like growth factor axis and risk of type 2 diabetes in women","volume":"61","author":"Rajpathak","year":"2012","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ghir.2025.101669_bb0090","doi-asserted-by":"crossref","first-page":"e1552","DOI":"10.1210\/clinem\/dgaa963","article-title":"Insulin-like growth factor-1, bone mineral density, and fracture: a Mendelian randomization study","volume":"106","author":"Yuan","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.ghir.2025.101669_bb0095","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1210\/jc.2016-1257","article-title":"Reference values for IGF-I serum concentrations: comparison of six immunoassays","volume":"101","author":"Chanson","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2025.101669_bb0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clinbiochem.2022.06.009","article-title":"Bias in IGF-1 concentrations and interpretation across three different clinical laboratory assays","volume":"108","author":"Mohammed-Ali","year":"2022","journal-title":"Clin. Biochem."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637425000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637425000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:16:39Z","timestamp":1763464599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637425000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":20,"alternative-id":["S1096637425000334"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2025.101669","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic changes in IGF-1 levels during cabergoline therapy in prolactinoma","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2025.101669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101669"}}